Alpha Tau Medical Ltd. (DRTS)
Alpha Tau Medical Statistics
Share Statistics
Alpha Tau Medical has 70.38M shares outstanding. The number of shares has increased by 0.84% in one year.
| Shares Outstanding | 70.38M |
| Shares Change (YoY) | 0.84% |
| Shares Change (QoQ) | 0.65% |
| Owned by Institutions (%) | 1.4% |
| Shares Floating | 51.99M |
| Failed to Deliver (FTD) Shares | 11K |
| FTD / Avg. Volume | 17.28% |
Short Selling Information
The latest short interest is 88.05K, so 0.13% of the outstanding shares have been sold short.
| Short Interest | 88.05K |
| Short % of Shares Out | 0.13% |
| Short % of Float | 0.17% |
| Short Ratio (days to cover) | 2.79 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -7.46. Alpha Tau Medical's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -7.46 |
| PS Ratio | 0 |
| Forward PS | 0.7 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Alpha Tau Medical.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.4, with a Debt / Equity ratio of 0.2.
| Current Ratio | 7.4 |
| Quick Ratio | 7.4 |
| Debt / Equity | 0.2 |
| Debt / EBITDA | -0.45 |
| Debt / FCF | -0.57 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-233.26K |
| Employee Count | 125 |
| Asset Turnover | null |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 16K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 8.75% in the last 52 weeks. The beta is 0.93, so Alpha Tau Medical's price volatility has been higher than the market average.
| Beta | 0.93 |
| 52-Week Price Change | 8.75% |
| 50-Day Moving Average | 2.68 |
| 200-Day Moving Average | 2.63 |
| Relative Strength Index (RSI) | 51.52 |
| Average Volume (20 Days) | 63.67K |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.07M |
| Operating Income | 35.68M |
| Net Income | -29.16M |
| EBITDA | -28.03M |
| EBIT | -29.1M |
| Earnings Per Share (EPS) | -0.42 |
Balance Sheet
The company has 13.72M in cash and 12.54M in debt, giving a net cash position of 1.19M.
| Cash & Cash Equivalents | 13.72M |
| Total Debt | 12.54M |
| Net Cash | 1.19M |
| Retained Earnings | -147.51M |
| Total Assets | 86.2M |
| Working Capital | 55.55M |
Cash Flow
In the last 12 months, operating cash flow was -19.78M and capital expenditures -2.24M, giving a free cash flow of -22.02M.
| Operating Cash Flow | -19.78M |
| Capital Expenditures | -2.24M |
| Free Cash Flow | -22.02M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DRTS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for DRTS is $8, which is 206.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 206.5% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 1.91 |
| Piotroski F-Score | 3 |